russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2022-5069russjcardiol-5069Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWГенетические полиморфизмы, ассоциированные с развитием аритмического типа сердечно-сосудистых событийGenetic polymorphisms associated with the development of arrhythmic type of cardiovascular eventshttps://orcid.org/0000-0002-7133-1689ГиматдиноваГ. Р.GimatdinovaG. R.

Гелия Рифкатовна Гиматдинова — очный аспирант кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара

Samara

gimatdinova1995@icolud.comhttps://orcid.org/0000-0002-4322-0447ДаниловаО. Е.DanilovaO. E.

Олеся Евгеньевна Данилова — кандидат медицинских наук, доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара

Samara

dani29051978@yandex.ruhttps://orcid.org/0000-0003-0645-7645ДавыдкинИ. Л.DavydkinI. L.

Игорь Леонидович Давыдкин — доктор медицинских наук, профессор кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара

Samara

dagi2006@rambler.ruhttps://orcid.org/0000-0002-7983-642XХайретдиновР. К.KhairetdinovR. K.

Раис Кэтдусович Хайретдинов — кандидат медицинских наук, доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара

Samara

doctorrais@mail.ruhttps://orcid.org/0000-0003-2851-7995АнтиповаА. В.AntipovaA. V.

Анжелика Владимировна Антипова — клинический ординатор кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара

Samara

anzhelikaantipova1996@gmail.ruФГБОУ ВО Самарский государственный медицинский университет Минздрава РоссииРоссияSamara State Medical UniversityRussian Federation202214092022273SОбразование50695069Copyright © Гиматдинова Г.Р., Данилова О.Е., Давыдкин И.Л., Хайретдинов Р.К., Антипова А.В., 20222022Гиматдинова Г.Р., Данилова О.Е., Давыдкин И.Л., Хайретдинов Р.К., Антипова А.В.Gimatdinova G.R., Danilova O.E., Davydkin I.L., Khairetdinov R.K., Antipova A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5069

В обзоре проанализирована глобальная повестка в отношении особенностей мутационного статуса генов, ассоциированных с развитием неблагоприятных сердечно-сосудистых событий аритмического типа, путем изучения подобранных данных из достоверных литературных медицинских источников. Полноэкзомное секвенирование генов позволит выделить группу риска по вероятности наступления ранних или отсроченных сердечно-сосудистых событий аритмического типа, в особенности среди пациентов, получающих терапию кардиотоксическими противоопухолевыми препаратами. Выделенная актуальная панель генетических полиморфизмов даст возможность оптимизировать подход к ведению пациентов, основываясь не только на клинических, лабораторно-инструментальных и анамнестических данных.

The review analyzes the global agenda on mutational status of genes associated with adverse cardiovascular events of arrhythmic type. Whole exome sequencing will identify a risk group for the likelihood of early or delayed cardiovascular events of arrhythmic type, especially among patients receiving anticancer therapy with cardiotoxic drugs. The dedicated up-to-date panel of genetic polymorphisms will provide an opportunity to optimize management of patients, based on not only clinical, paraclinical and anamnestic data.

генетические полиморфизмыкардиотоксичностьонкогематологияаритмиигенетикаgenetic polymorphismscardiotoxicityoncohematologyarrhythmiasgeneticsReferencesКаприн А. Д., Старинский В.В., Шахзадова А. О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ "НМИЦ радиологии" МЗ РФ. 2022; 239 с. ISBN: 978-5-85502-275-9.Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care to the population of Russia in 2021. Moscow: P. A. Herzen Institute of Oncology — branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia, 2022; p. 239. (In Russ.). ISBN: 978-5-85502-275-9.Ye L, Yang Z, Selvanayagam J, et al. Myocardial Strain Imaging by Echocardiography for the Prediction of Cardiotoxicity in Chemotherapy-Treated Patients: A Meta-Analysis. JACC Cardiovascular Imaging. 2020;13(3):881-2. doi:10.1016/j.jcmg.2019.09.013.Ye L, Yang Z, Selvanayagam J, et al. Myocardial Strain Imaging by Echocardiography for the Prediction of Cardiotoxicity in Chemotherapy-Treated Patients: A Meta-Analysis. JACC Cardiovascular Imaging. 2020;13(3):881-2. doi:10.1016/j.jcmg.2019.09.013.Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703. doi:10.15829/1560-4071-2021-4703.Vasyuk YA, Gendlin GE, Emelina EI, et al. The agreed opinion of Russian experts on the prevention, diagnosis and treatment of cardiovascular toxicity of antitumor therapy. Russian Journal of Cardiology. 2021;26(9):4703. (In Russ.) doi:10.15829/1560-4071-2021-4703.Кузьмина Т.П., Давыдкин И.Л., Терешина О.В. и др. Кардиотоксичность и методы ее диагностики у пациентов гематологического профиля (обзор литературы). Сибирский научный медицинский журнал. 2019;39(1):34-42. doi:10.15372/SSMJ20190105.Kuzmina TP, Davydkin IL, Tereshina OV, et al. Cardiotoxicity and methods of its diagnosis in hematological patients (literature review). Siberian Scientific Medical Journal. 2019;39(1):34-42. (In Russ.) doi:10.15372/SSMJ20190105.Yang H, Hu Z, Zhuang C, et al. Association between the polymorphisms of CALM1 gene and osteoarthritis risk: a meta-analysis based on observational studies. Bioscience Reports. 2018;38(5):BSR20181128. doi:10.1042/BSR20181128.Yang H, Hu Z, Zhuang C, et al. Association between the polymorphisms of CALM1 gene and osteoarthritis risk: a meta-analysis based on observational studies. Bioscience Reports. 2018;38(5):BSR20181128. doi:10.1042/BSR20181128.Гиматдинова Г.Р., Данилова О.Е., Давыдкин И.Л. и др. Современные аспекты ранней диагностики кардиотоксических осложнений лекарственной терапии в онкологии (обзор литературы). Клиническая онкогематология. 2022;15(1):107-13. doi:10.21320/2500-2139-2022-15-1-107-113.Gimatdinova GR, Danilova OE, Davydkin IL, et al. Modern aspects of early diagnosis of cardiotoxic complications of drug therapy in oncology (literature review). Clinical oncohematology. 2022;15(1):107-13. (In Russ.) doi:10.21320/2500-2139-2022-15-1-107-113.Avila M, Ayub-Ferreira S, Wanderley M, et al. Carvedilol for Prevention of ChemotherapyRelated Cardiotoxicity: The CECCY Trial. J of the American College of Cardiology. 2018;71(20):2281-90. doi:10.1016/j.jacc.2018.02.049.Avila M, Ayub-Ferreira S, Wanderley M, et al. Carvedilol for Prevention of ChemotherapyRelated Cardiotoxicity: The CECCY Trial. J of the American College of Cardiology. 2018;71(20):2281-90. doi:10.1016/j.jacc.2018.02.049.Li Q, Du Q. Associations between nine candidate genetic polymorphisms with coronary heart disease: A meta-analysis. Herz. 2020;45(1):15-28. doi:10.1007/s00059-019-4806-7.Li Q, Du Q. Associations between nine candidate genetic polymorphisms with coronary heart disease: A meta-analysis. Herz. 2020;45(1):15-28. doi:10.1007/s00059-019-4806-7.Ignatieva E, Smolina N, Kostareva A, et al. Skeletal Muscle Mitochondria Dysfunction in Genetic Neuromuscular Disorders with Cardiac Phenotype. Int. J. Mol. Sci. 2021;22(14):7349. doi:10.3390/ijms22147349.Ignatieva E, Smolina N, Kostareva A, et al. Skeletal Muscle Mitochondria Dysfunction in Genetic Neuromuscular Disorders with Cardiac Phenotype. Int. J. Mol. Sci. 2021;22(14):7349. doi:10.3390/ijms22147349.Kim Y, Seidman JG, Seidman CE. Genetics of cancer therapy-associated cardiotoxicity. Journal of Molecular and Cellular Cardiology. 2022;167:85-91. doi:10.1016/j.yjmcc.2022.03.010.Kim Y, Seidman JG, Seidman CE. Genetics of cancer therapy-associated cardiotoxicity. Journal of Molecular and Cellular Cardiology. 2022;167:85-91. doi:10.1016/j.yjmcc.2022.03.010.Гвалдин Д.Ю., Тимошкина Н.Н., Ващенко Л.Н. и др. Уровень RS4673 и pon1 в плазме крови — новые перспективы в прогнозировании и ранней диагностике антрациклин-опосредованной кардиотоксичности. Клинический лабораторный диагноз. 2022;67(2):123-8. doi:10.51620/0869-2084-2022-67-2-123-128.Gvaldin DY, Timoshkina NN, Vashchenko LN, et al. The level of RS4673 and pon1 in blood plasma is a new perspective in the prediction and early diagnosis of anthracyclinemediated cardiotoxicity. Clinical laboratory diagnosis. 2022;67(2):123-8. (In Russ.) doi:10.51620/0869-2084-2022-67-2-123-128.Vulsteke C, Pfeil AM, Maggen C, et al. Clinical and genetic risk factors for epirubicininduced cardiac toxicity in early breast cancer patients. Breast Cancer Research and Treatment. 2015;152(1):67-76. doi:10.1007/s10549-015-3437-9.Vulsteke C, Pfeil AM, Maggen C, et al. Clinical and genetic risk factors for epirubicininduced cardiac toxicity in early breast cancer patients. Breast Cancer Research and Treatment. 2015;152(1):67-76. doi:10.1007/s10549-015-3437-9.Bhagat A, Kleinerman E. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms and Prevention. Advances in Experimental Medicine and Biology. 2020;1257:181-92. doi:10.1007/978-3-030-43032-0_15.Bhagat A, Kleinerman E. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms and Prevention. Advances in Experimental Medicine and Biology. 2020;1257:181-92. doi:10.1007/978-3-030-43032-0_15.Michel L, Mincu R, Mrotzek S, et al. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis. ESC Heart Failure. 2020;7(2):423-33. doi:10.1002/ehf2.12589.Michel L, Mincu R, Mrotzek S, et al. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis. ESC Heart Failure. 2020;7(2):423-33. doi:10.1002/ehf2.12589.Michel L, Mincu R, Mahabadi A, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. European Journal of Heart Failure. 2020;22(2):350-61. doi:10.1002/ejhf.1631.Michel L, Mincu R, Mahabadi A, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. European Journal of Heart Failure. 2020;22(2):350-61. doi:10.1002/ejhf.1631.Marstrand P, Almatlouh K, Kanters J, et al. Long QT syndrome type 1 and 2 patients respond differently to arrhythmic triggers: The Tri Qarr in vivo study. Heart Rhythm. 2021;18(2):241-9. doi:10.1016/j.hrthm.2020.08.017.Marstrand P, Almatlouh K, Kanters J, et al. Long QT syndrome type 1 and 2 patients respond differently to arrhythmic triggers: The Tri Qarr in vivo study. Heart Rhythm. 2021;18(2):241-9. doi:10.1016/j.hrthm.2020.08.017.Kotta M, Sala L, Ghidoni A, et al. Calmodulinopathy: A Novel, Life-Threatening Clinical Entity Affecting the Young. Frontiers in Cardiovascular Medicine. 2018;5:175. doi:10.3389/fcvm.2018.00175.Kotta M, Sala L, Ghidoni A, et al. Calmodulinopathy: A Novel, Life-Threatening Clinical Entity Affecting the Young. Frontiers in Cardiovascular Medicine. 2018;5:175. doi:10.3389/fcvm.2018.00175.George A. The importance of being selective. Heart Rhythm. 2019;16(2):279-80. doi:10.1016/j.hrthm.2018.09.022.George A. The importance of being selective. Heart Rhythm. 2019;16(2):279-80. doi:10.1016/j.hrthm.2018.09.022.Crotti L, Spazzolini C, Tester D, et al. Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal. 2019;40(35):2964-75. doi:10.1093/eurheartj/ehz311.Crotti L, Spazzolini C, Tester D, et al. Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal. 2019;40(35):2964-75. doi:10.1093/eurheartj/ehz311.Zahavich L, Tarnopolsky M, Yao R, et al. Novel Association of a De Novo CALM2 Mutation with Long QT Syndrome and Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2018;11(10):e002255. doi:10.1161/CIRCGEN.118.002255.Zahavich L, Tarnopolsky M, Yao R, et al. Novel Association of a De Novo CALM2 Mutation with Long QT Syndrome and Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2018;11(10):e002255. doi:10.1161/CIRCGEN.118.002255.Schwartz P, Gnecchi M, Dagradi F, et al. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal. 2019;40(23):1832-6. doi:10.1093/eurheartj/ehz023.Schwartz P, Gnecchi M, Dagradi F, et al. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal. 2019;40(23):1832-6. doi:10.1093/eurheartj/ehz023.Kumar A, Rani B, Sharma R, et al. ACE2, CALM3 and TNNI3K polymorphisms as potential disease modifiers in hypertrophic and dilated cardiomyopathies. Clinical trial molecular and cellular biochemistry. 2018;438(1-2):167-74. doi:10.1007/s11010-017-3123-9.Kumar A, Rani B, Sharma R, et al. ACE2, CALM3 and TNNI3K polymorphisms as potential disease modifiers in hypertrophic and dilated cardiomyopathies. Clinical trial molecular and cellular biochemistry. 2018;438(1-2):167-74. doi:10.1007/s11010-017-3123-9.Papatheodorou I, Fonseca N, Keays M, et al. Expression Atlas: gene and protein expression across multiple studies and organisms. Nucleic Acids Research. 2018;46(1):246-51. doi:10.1093/nar/gkx1158.Papatheodorou I, Fonseca N, Keays M, et al. Expression Atlas: gene and protein expression across multiple studies and organisms. Nucleic Acids Research. 2018;46(1):246-51. doi:10.1093/nar/gkx1158.Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М. и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;26(7):4600. doi:10.15829/1560-4071-2021-4600.Lebedev DS, Mikhailov EN, Neminushchy NM, et al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2020;26(7):4600. (In Russ.) doi:10.15829/1560-4071-2021-4600.Fan S, Meng J, Zhang L, et al. CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. Pathology - Research and Practice. 2019;215(1):151-8. doi:10.1016/j.prp.2018.11.009.Fan S, Meng J, Zhang L, et al. CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. Pathology - Research and Practice. 2019;215(1):151-8. doi:10.1016/j.prp.2018.11.009.Geng T, Feng L, Fang Y, et al. Association between caveolin-1 and stroke: a systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences. 2020;24(19):10054-60. doi:10.26355/eurrev_202010_23221.Geng T, Feng L, Fang Y, et al. Association between caveolin-1 and stroke: a systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences. 2020;24(19):10054-60. doi:10.26355/eurrev_202010_23221.Tyan L, Turner D, Komp K, et al. Caveolin-3 is required for regulation of transient outward potassium current by angiotensin II in mouse atrial myocytes. American Journal of Physiology - Heart and Circulatory. 2021;320(2):787-97. doi:10.1152/ajpheart.00569.2020.Tyan L, Turner D, Komp K, et al. Caveolin-3 is required for regulation of transient outward potassium current by angiotensin II in mouse atrial myocytes. American Journal of Physiology - Heart and Circulatory. 2021;320(2):787-97. doi:10.1152/ajpheart.00569.2020.Максимов В.Н., Иванощук Д.Е., Орлов П.С. и др. Первые результаты секвенирования панели генов при внезапной сердечной смерти молодых мужчин. Медицинская генетика. 2020;19;(5):36-8. doi:10.25557/2073-7998.2020.05.36-38.Maksimov VN, Ivanoshchuk DE, Orlov PS, et al. The first results of sequencing a panel of genes in sudden cardiac death of young men. Medical genetics. 2020;19;(5):36-8. (In Russ.) doi:10.25557/2073-7998.2020.05.36-38.Mehboob R, Kurdi M, Ahmad M, et al. Comprehensive Analysis of Genes Associated with Sudden Infant Death Syndrome. Frontiers in Pediatrics. 2021;9:742225. doi:10.3389/fped.2021.742225.Mehboob R, Kurdi M, Ahmad M, et al. Comprehensive Analysis of Genes Associated with Sudden Infant Death Syndrome. Frontiers in Pediatrics. 2021;9:742225. doi:10.3389/fped.2021.742225.Zhanga W, Maa K, Hanb N. Probucol recovers pathological damage in viral Myocarditis through improvement of myocardium-related proteins. Microbial Pathogenesis. 2020;147:104257. doi:10.1016/j.micpath.2020.104257.Zhanga W, Maa K, Hanb N. Probucol recovers pathological damage in viral Myocarditis through improvement of myocardium-related proteins. Microbial Pathogenesis. 2020;147:104257. doi:10.1016/j.micpath.2020.104257.Al-Akchar M, Siddique M. Long QT Syndrome. Treasure Island (FL): Stat Pearls Publishing. 2022.Al-Akchar M, Siddique M. Long QT Syndrome. Treasure Island (FL): Stat Pearls Publishing. 2022.Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. и др. Внезапная сердечная смерть. М: ГЭОТАР-Медиа, 2020, с. 352. doi:10.33029/9704-5629-3-SCD-2020-1-352.Bokeria LA, Revishvili AS, Neminushchy NM, et al. Sudden cardiac death. Moscow: GEOTAR-Media, 2020, р. 352. (In Russ.) doi:10.33029/9704-5629-3-SCD-2020-1-352.Clemens D, Tester D, Giudicessi J, et al. International Triadin Knockout Syndrome Registry. Circulation genomic and precision medicine. 2019;12(2):e002419. doi:10.1161/CIRCGEN.118.002419.Clemens D, Tester D, Giudicessi J, et al. International Triadin Knockout Syndrome Registry. Circulation genomic and precision medicine. 2019;12(2):e002419. doi:10.1161/CIRCGEN.118.002419.O’Callaghan B, Hancox J, Stuart A, et al. A unique triadin exon deletion causing a null phenotype. Heartrhythm Case Reports. 2018;4(11):514-8. doi:10.1016/j.hrcr.2018.07.014.O’Callaghan B, Hancox J, Stuart A, et al. A unique triadin exon deletion causing a null phenotype. Heartrhythm Case Reports. 2018;4(11):514-8. doi:10.1016/j.hrcr.2018.07.014.Rossi D, Gigli L, Gamberucci A, et al. A novel homozygous mutation in the TRDN gene causes a severe form of pediatric malignant ventricular arrhythmia. Heart Rhythm. 2020;17(2):296-304. doi:10.1016/j.hrthm.2019.08.018.Rossi D, Gigli L, Gamberucci A, et al. A novel homozygous mutation in the TRDN gene causes a severe form of pediatric malignant ventricular arrhythmia. Heart Rhythm. 2020;17(2):296-304. doi:10.1016/j.hrthm.2019.08.018.Roberts J, Asaki S, Mazzanti A, et al. An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Circulation. 2020;141(6):429-39. doi:10.1161/CIRCULATIONAHA.119.043114.Roberts J, Asaki S, Mazzanti A, et al. An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Circulation. 2020;141(6):429-39. doi:10.1161/CIRCULATIONAHA.119.043114.Sedaghat-Hamedani F, Rebs S, El-Battrawy I, et al. Identification of SCN5a p.C335R Variant in a Large Family with Dilated Cardiomyopathy and Conduction Disease. International Journal of Molecular Sciences. 2021;22(23):12990. doi:10.3390/ijms222312990.Sedaghat-Hamedani F, Rebs S, El-Battrawy I, et al. Identification of SCN5a p.C335R Variant in a Large Family with Dilated Cardiomyopathy and Conduction Disease. International Journal of Molecular Sciences. 2021;22(23):12990. doi:10.3390/ijms222312990.Basso C, Pilichou K, Bauce B, et al. Diagnostic Criteria, Genetics, and Molecular Basis of Arrhythmogenic Cardiomyopathy. Heart Failure Clinics. 2018;14(2):201-13. doi:10.1016/j.hfc.2018.01.002.Basso C, Pilichou K, Bauce B, et al. Diagnostic Criteria, Genetics, and Molecular Basis of Arrhythmogenic Cardiomyopathy. Heart Failure Clinics. 2018;14(2):201-13. doi:10.1016/j.hfc.2018.01.002.Mikhailova VB, Karpushev AV, Vavilova VD, et al. Functional Analysis of SCN5A Genetic Variants Associated with Brugada Syndrome. Cardiology. 2022;147(1):35-46. doi:10.1159/000519857.Mikhailova VB, Karpushev AV, Vavilova VD, et al. Functional Analysis of SCN5A Genetic Variants Associated with Brugada Syndrome. Cardiology. 2022;147(1):35-46. doi:10.1159/000519857.Hull J, Isom L. Voltage-gated sodium channel β subunits: The power outside the pore in brain development and disease. Neuropharmacology. 2018;132:43-57. doi:10.1016/j.neuropharm.2017.09.018.Hull J, Isom L. Voltage-gated sodium channel β subunits: The power outside the pore in brain development and disease. Neuropharmacology. 2018;132:43-57. doi:10.1016/j.neuropharm.2017.09.018.Li W, Yin L, Shen C, et al. SCN5A Variants: Association with Cardiac Disorders. Frontiers in Physiology. 2018;9:1372. doi:10.3389/fphys.2018.01372.Li W, Yin L, Shen C, et al. SCN5A Variants: Association with Cardiac Disorders. Frontiers in Physiology. 2018;9:1372. doi:10.3389/fphys.2018.01372.Rico Y, Ramis M, Massot M, et al. Familial Dilated Cardiomyopathy and Sudden Cardiac Arrest: New Association with a SCN5A Mutation. Genes (Basel). 2021;12(12):1889. doi:10.3390/genes12121889.Rico Y, Ramis M, Massot M, et al. Familial Dilated Cardiomyopathy and Sudden Cardiac Arrest: New Association with a SCN5A Mutation. Genes (Basel). 2021;12(12):1889. doi:10.3390/genes12121889.Chen R, Chung S. Inhibition of Voltage-Gated K+ Channel Kv1.5 by Antiarrhythmic Drugs. Biochemistry. 2018;57(18):2704-10. doi:10.1021/acs.biochem.8b00268.Chen R, Chung S. Inhibition of Voltage-Gated K+ Channel Kv1.5 by Antiarrhythmic Drugs. Biochemistry. 2018;57(18):2704-10. doi:10.1021/acs.biochem.8b00268.Zhao Z, Ruan S, Ma X, et al. Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5. Biomolecules. 2019;10(1):10. doi:10.3390/biom10010010.Zhao Z, Ruan S, Ma X, et al. Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5. Biomolecules. 2019;10(1):10. doi:10.3390/biom10010010.Wang Y, Eldstrom J, Fedida D. Gating and Regulation of KCNQ1 and KCNQ1 + KCNE1 Channel Complexes. Frontiers in Physiology. 2020;11:504. doi:10.3389/fphys.2020.00504.Wang Y, Eldstrom J, Fedida D. Gating and Regulation of KCNQ1 and KCNQ1 + KCNE1 Channel Complexes. Frontiers in Physiology. 2020;11:504. doi:10.3389/fphys.2020.00504.Yang Z, Ma Y, Huang J, et al. Digenic heterozygous mutations of KCNH2 and SCN5A induced young and early-onset long QT syndrome and sinoatrial node dysfunction. Annals of Noninvasive Electrocardiology. 2022;27(1):e12889. doi:10.1111/anec.12889.Yang Z, Ma Y, Huang J, et al. Digenic heterozygous mutations of KCNH2 and SCN5A induced young and early-onset long QT syndrome and sinoatrial node dysfunction. Annals of Noninvasive Electrocardiology. 2022;27(1):e12889. doi:10.1111/anec.12889.Boogaard M, Weerd J, Bawazeer A, et al. Identification and Characterization of a Transcribed Distal Enhancer Involved in Cardiac Kcnh2 Regulation. Cell Reports. 2019;28(10):2704-14.e5. doi:10.1016/j.celrep.2019.08.007.Boogaard M, Weerd J, Bawazeer A, et al. Identification and Characterization of a Transcribed Distal Enhancer Involved in Cardiac Kcnh2 Regulation. Cell Reports. 2019;28(10):2704-14.e5. doi:10.1016/j.celrep.2019.08.007.Yazdi S, Nikesjö J, Miranda W, et al. Identification of PUFA interaction sites on the cardiac potassium channel KCNQ1. The Journal of General Physiology. 2021;153(6):e202012850. doi:10.1085/jgp.202012850.Yazdi S, Nikesjö J, Miranda W, et al. Identification of PUFA interaction sites on the cardiac potassium channel KCNQ1. The Journal of General Physiology. 2021;153(6):e202012850. doi:10.1085/jgp.202012850.Сивцев А.А., Свинцова Л.И., Плотникова И.В. и др. Анализ спектра мутаций в генах KCNQ1, KCNH2 и SCN5A у больных с синдромом удлиненного интервала QT с использованием массового параллельного секвенирования. Медицинская генетика. 2020;19(5):20-2. doi:10.25557/2073-7998.2020.05.20-22.Sivtsev AA, Svintsova LI, Plotnikova IV, et al. Analysis of the spectrum of mutations in the KCNQ1, KCNH2 and SCN5A genes in patients with long QT syndrome using mass parallel sequencing. Medical genetics. 2020;19(5):20-2. (In Russ.) doi:10.25557/2073-7998.2020.05.20-22.Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology. 2020;17(8):474-502. doi:10.1038/s41569-020-0348-1.Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology. 2020;17(8):474-502. doi:10.1038/s41569-020-0348-1.

The authors declare that there are no conflicts of interest present.